TN2009000050A1 - Production method of methane gas from olive mill waste - Google Patents
Production method of methane gas from olive mill wasteInfo
- Publication number
- TN2009000050A1 TN2009000050A1 TN2009000050A TN2009000050A TN2009000050A1 TN 2009000050 A1 TN2009000050 A1 TN 2009000050A1 TN 2009000050 A TN2009000050 A TN 2009000050A TN 2009000050 A TN2009000050 A TN 2009000050A TN 2009000050 A1 TN2009000050 A1 TN 2009000050A1
- Authority
- TN
- Tunisia
- Prior art keywords
- methane gas
- olive mill
- mill wastewater
- secondary sludge
- sludge
- Prior art date
Links
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 title abstract 8
- 240000007817 Olea europaea Species 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000002699 waste material Substances 0.000 title 1
- 239000010802 sludge Substances 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 239000002351 wastewater Substances 0.000 abstract 4
- 239000007789 gas Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 230000000813 microbial effect Effects 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 239000010865 sewage Substances 0.000 abstract 2
- 238000012258 culturing Methods 0.000 abstract 1
- 230000029087 digestion Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82516806P | 2006-09-11 | 2006-09-11 | |
| PCT/KR2006/005503 WO2008038860A1 (en) | 2006-09-26 | 2006-12-15 | Production method of methane gas from olive mill waste |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2009000050A1 true TN2009000050A1 (en) | 2010-08-19 |
Family
ID=39032357
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TN2009000050A TN2009000050A1 (en) | 2006-09-11 | 2009-02-17 | Production method of methane gas from olive mill waste |
| TN2009000049A TN2009000049A1 (en) | 2006-09-11 | 2009-02-17 | A pyrrolopyrazin as syk-kinase inhibitor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TN2009000049A TN2009000049A1 (en) | 2006-09-11 | 2009-02-17 | A pyrrolopyrazin as syk-kinase inhibitor |
Country Status (32)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2372908T3 (es) | 2008-02-25 | 2012-01-27 | F. Hoffmann-La Roche Ag | Inhibidores de la pirrolopirazina quinasa. |
| PL2247592T3 (pl) | 2008-02-25 | 2012-01-31 | Hoffmann La Roche | Pirolopirazynowe inhibitory kinazy |
| EP2247595B1 (en) | 2008-02-25 | 2011-07-20 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
| CN101952294B (zh) | 2008-02-25 | 2014-11-26 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪激酶抑制剂 |
| KR20100114095A (ko) | 2008-02-25 | 2010-10-22 | 에프. 호프만-라 로슈 아게 | 피롤로피라진 키나아제 저해제 |
| NZ587906A (en) * | 2008-03-10 | 2011-12-22 | Sanofi Aventis | Treatment for ocular-related disorders |
| FR2929851B1 (fr) * | 2008-04-09 | 2012-11-30 | Centre Nat Rech Scient | Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules |
| PA8851701A1 (es) | 2008-12-03 | 2010-07-27 | Sanofi Aventis | Tratamiento para la glomerulonefritis |
| CN102239169A (zh) * | 2008-12-04 | 2011-11-09 | 赛诺菲 | 结晶形式 |
| TW201034675A (en) * | 2008-12-18 | 2010-10-01 | Sanofi Aventis | Method for treating macular degeneration |
| US20110112101A1 (en) * | 2009-03-05 | 2011-05-12 | Sanofi-Aventis | Treatment for ocular-related disorders |
| AR075869A1 (es) * | 2009-03-19 | 2011-05-04 | Sanofi Aventis | Sintesis de azaindoles |
| PL2516434T3 (pl) | 2009-12-23 | 2015-11-30 | Takeda Pharmaceuticals Co | Skondensowane heteroaromatyczne pirolidynony jako inhibitory SYK |
| US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| US8481541B2 (en) | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| JP2013529204A (ja) * | 2010-05-20 | 2013-07-18 | エフ．ホフマン−ラ ロシュ アーゲー | ピロロ［２，３−ｂ］ピラジン−７−カルボキサミド誘導体とＪＡＫ及びＳＹＫ及び阻害剤としてのそれらの使用 |
| CA2798970A1 (en) | 2010-05-20 | 2011-11-24 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives as syk and jak inhibitors |
| EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
| EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
| US9056873B2 (en) | 2011-06-22 | 2015-06-16 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
| EP2888262B1 (en) * | 2012-08-21 | 2018-12-19 | F.Hoffmann-La Roche Ag | Pyrrolo[2,3-b]pyrazines as syk inhibitors |
| KR101750667B1 (ko) | 2013-07-31 | 2017-07-04 | 길리애드 사이언시즈, 인코포레이티드 | Syk 억제제 |
| KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN116969927B (zh) * | 2023-06-07 | 2024-03-19 | 中南民族大学 | 一种从荜茇中提取分离的化合物及该化合物在制备抗炎药物中的应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1141949A (en) * | 1966-02-23 | 1969-02-05 | Sterling Drug Inc | 7-azaindole derivatives |
| US3992392A (en) * | 1973-04-27 | 1976-11-16 | The Ohio State University Research Foundation | Synthesis of indoles from anilines and intermediates therein |
| SE9100920D0 (sv) | 1991-03-27 | 1991-03-27 | Astra Ab | New active compounds |
| GB9226855D0 (en) * | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| US6075037A (en) | 1994-06-09 | 2000-06-13 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| FR2732969B1 (fr) | 1995-04-14 | 1997-05-16 | Adir | Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6180643B1 (en) | 1996-11-19 | 2001-01-30 | Amgen Inc. | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents |
| US6312835B1 (en) | 1997-02-13 | 2001-11-06 | Queen's University At Kingston | Luminescent compounds and methods of making and using same |
| JP2001516353A (ja) | 1997-03-19 | 2001-09-25 | ビーエーエスエフ アクチェンゲゼルシャフト | ピロロ［２，３ｄ］ピリミジンおよびチロシンキナーゼ阻害剤としてのこれらの使用 |
| WO1998047899A1 (en) | 1997-04-24 | 1998-10-29 | Ortho-Mcneil Corporation, Inc. | Substituted pyrrolopyridines useful in the treatment of inflammatory diseases |
| CN1264381A (zh) | 1997-08-05 | 2000-08-23 | 辉瑞产品公司 | 4－氨基吡咯并(3,2－d)嘧啶作为神经肽Y受体拮抗药 |
| PL340412A1 (en) | 1997-10-20 | 2001-01-29 | Hoffmann La Roche | Bicyclic kinase inhibitors |
| WO1999045016A2 (en) | 1998-03-06 | 1999-09-10 | Metabasis Therapeutics, Inc. | Novel prodrugs for phosphorus-containing compounds |
| CA2326140A1 (en) | 1998-04-02 | 1999-10-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| JP2002510630A (ja) | 1998-04-02 | 2002-04-09 | メルク エンド カムパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモン拮抗薬 |
| ATE482945T1 (de) | 1998-05-26 | 2010-10-15 | Chugai Pharmaceutical Co Ltd | Heterozyklische indolderivate und mono- oder diazaindol-derivate |
| HK1039325B (en) | 1998-09-18 | 2006-02-24 | Abbott Gmbh & Co. Kg | 4-aminopyrrolopyrimidines as kinase inhibitors |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| CN1615873A (zh) * | 1999-12-24 | 2005-05-18 | 阿文蒂斯药物有限公司 | 氮杂吲哚类化合物 |
| GB9930698D0 (en) * | 1999-12-24 | 2000-02-16 | Rhone Poulenc Rorer Ltd | Chemical compounds |
| US6770666B2 (en) * | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| DE10009000A1 (de) * | 2000-02-25 | 2001-08-30 | Basf Ag | Verfahren zur Herstellung substituierter Indole |
| US20030225036A1 (en) * | 2000-03-20 | 2003-12-04 | Aleksandr Kolesnikov | Non-amidine containing protease inhibitors |
| JP2001302667A (ja) * | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| WO2001082930A1 (en) * | 2000-05-03 | 2001-11-08 | Tularik Inc. | Pyrazole antimicrobial agents |
| WO2001096336A2 (en) | 2000-06-14 | 2001-12-20 | Warner-Lambert Company | 6,5-fused bicyclic heterocycles |
| EP1324985A4 (en) | 2000-10-02 | 2004-10-06 | Merck & Co Inc | PRENYL PROTEIN TRANSFERASE INHIBITORS |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| WO2003000690A1 (en) | 2001-06-25 | 2003-01-03 | Aventis Pharmaceuticals Inc. | Synthesis of heterocyclic compounds employing microwave technology |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| EP1441725A1 (en) | 2001-10-26 | 2004-08-04 | Aventis Pharmaceuticals Inc. | Benzimidazoles and analogues and their use as protein kinases inhibitors |
| US20040082365A1 (en) * | 2002-07-18 | 2004-04-29 | Celerica Ltd | Digitization and transmitting cellular RF signals by several light wavelengths |
| EP1388541A1 (en) | 2002-08-09 | 2004-02-11 | Centre National De La Recherche Scientifique (Cnrs) | Pyrrolopyrazines as kinase inhibitors |
| WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用 |
| AU2005269387A1 (en) * | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| FR2876582B1 (fr) | 2004-10-15 | 2007-01-05 | Centre Nat Rech Scient Cnrse | Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
| AU2005304952B2 (en) | 2004-11-08 | 2013-04-04 | Baxter Healthcare S.A. | Nanoparticulate compositions of tubulin inhibitors |
| EP1814882A1 (en) * | 2004-11-22 | 2007-08-08 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
| US20110112101A1 (en) * | 2009-03-05 | 2011-05-12 | Sanofi-Aventis | Treatment for ocular-related disorders |
-
2007
- 2007-09-10 CL CL200702617A patent/CL2007002617A1/es unknown
- 2007-09-11 EP EP07842207.8A patent/EP2094708B1/en active Active
- 2007-09-11 MY MYPI20090720A patent/MY148107A/en unknown
- 2007-09-11 RU RU2009113615/04A patent/RU2440352C2/ru not_active IP Right Cessation
- 2007-09-11 AR ARP070104013A patent/AR062745A1/es not_active Application Discontinuation
- 2007-09-11 TW TW096133786A patent/TWI399379B/zh not_active IP Right Cessation
- 2007-09-11 ES ES07842207.8T patent/ES2437318T3/es active Active
- 2007-09-11 BR BRPI0716781-4A2A patent/BRPI0716781A2/pt not_active IP Right Cessation
- 2007-09-11 CA CA2663175A patent/CA2663175C/en not_active Expired - Fee Related
- 2007-09-11 CN CN201310652393.XA patent/CN103804383A/zh active Pending
- 2007-09-11 AU AU2007296592A patent/AU2007296592B8/en not_active Ceased
- 2007-09-11 CN CNA2007800336608A patent/CN101511838A/zh active Pending
- 2007-09-11 NZ NZ575496A patent/NZ575496A/en not_active IP Right Cessation
- 2007-09-11 JP JP2009538434A patent/JP5161237B2/ja not_active Expired - Fee Related
- 2007-09-11 KR KR1020097005040A patent/KR101443056B1/ko not_active Expired - Fee Related
- 2007-09-11 DK DK07842207.8T patent/DK2094708T3/da active
- 2007-09-11 WO PCT/US2007/078103 patent/WO2008033798A2/en not_active Ceased
- 2007-09-11 UY UY30584A patent/UY30584A1/es not_active Application Discontinuation
- 2007-09-11 PE PE2007001220A patent/PE20081372A1/es not_active Application Discontinuation
- 2007-09-11 MX MX2009002616A patent/MX2009002616A/es active IP Right Grant
- 2007-09-11 PT PT78422078T patent/PT2094708E/pt unknown
- 2007-11-09 UA UAA200903417A patent/UA94622C2/ru unknown
-
2009
- 2009-02-16 ZA ZA2009/01073A patent/ZA200901073B/en unknown
- 2009-02-17 NI NI200900021A patent/NI200900021A/es unknown
- 2009-02-17 TN TN2009000050A patent/TN2009000050A1/fr unknown
- 2009-02-17 TN TN2009000049A patent/TN2009000049A1/fr unknown
- 2009-02-25 CR CR10636A patent/CR10636A/es not_active Application Discontinuation
- 2009-03-03 IL IL197381A patent/IL197381A/en not_active IP Right Cessation
- 2009-03-10 US US12/401,254 patent/US8658649B2/en not_active Expired - Fee Related
- 2009-03-10 HN HN2009000455A patent/HN2009000455A/es unknown
- 2009-03-10 GT GT200900055A patent/GT200900055A/es unknown
- 2009-03-11 CO CO09025278A patent/CO6160236A2/es unknown
- 2009-03-26 NO NO20091265A patent/NO20091265L/no not_active Application Discontinuation
- 2009-04-06 MA MA31765A patent/MA30781B1/fr unknown
-
2014
- 2014-01-28 US US14/166,396 patent/US20140142110A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2009000050A1 (en) | Production method of methane gas from olive mill waste | |
| Khan et al. | Optimization of process parameters for production of volatile fatty acid, biohydrogen and methane from anaerobic digestion | |
| Cavinato et al. | Optimization of two-phase thermophilic anaerobic digestion of biowaste for hydrogen and methane production through reject water recirculation | |
| Wacławek et al. | A novel approach for simultaneous improvement of dewaterability, post-digestion liquor properties and toluene removal from anaerobically digested sludge | |
| CN105859038B (zh) | 一种高效利用污泥中碳源的污水处理工艺 | |
| Xiao et al. | Evaluation and characterization during the anaerobic digestion of high-strength kitchen waste slurry via a pilot-scale anaerobic membrane bioreactor | |
| Trancone et al. | A combined system for asbestos-cement waste degradation by dark fermentation and resulting supernatant valorization in anaerobic digestion | |
| CN102796765A (zh) | 一种两相产氢产甲烷耦合反应处理易降解有机废弃物的方法 | |
| Gottardo et al. | Hydrogen and methane production from biowaste and sewage sludge by two phases anaerobic codigestion | |
| Mao et al. | System integration of hydrothermal liquefaction and anaerobic digestion for wet biomass valorization: Biodegradability and microbial syntrophy | |
| Demirer et al. | Two-phase thermophilic acidification and mesophilic methanogenesis anaerobic digestion of waste-activated sludge | |
| Bonu et al. | Impact of thermal pre-treatment on anaerobic co-digestion of sewage sludge and landfill leachate | |
| Munoz et al. | Impact of thermal hydrolysis on VFA-based carbon source production from fermentation of sludge and digestate for denitrification: experimentation and upscaling implications | |
| Peña-Picola et al. | Acidogenic fermentation of biowaste coupled with nitrogen recovery using selective membranes to produce a VFA-rich liquid with a high C/N ratio | |
| Pedizzi et al. | A combination of ammonia stripping and low temperature thermal pre-treatment improves anaerobic post-digestion of the supernatant from organic fraction of municipal solid waste treatment | |
| Isa et al. | Anaerobic treatment of ultrasound pretreated palm oil mill effluent (POME): microbial diversity and enhancement of biogas production | |
| Balasundaram et al. | Advanced steam explosion as thermal hydrolysis process for high solids anaerobic digestion and enhanced methane yield: proof of concept | |
| CA2468158A1 (en) | System and method for the production of biogas and compost | |
| Li et al. | Use of embedding immobilized biofillers to improve hydrolysis acidification efficiency in domestic wastewater treatment | |
| He et al. | Organic matter removal performance, pathway and microbial community succession during the construction of high-ammonia anaerobic biosystems treating anaerobic digestate food waste effluent | |
| CN105060622A (zh) | 三污泥污水碳氮磷同时去除及污泥稳定化处理方法 | |
| WO2007048537A8 (de) | Verfahren und reaktor zur anaeroben behandlung von abwasser mittels eines uasb | |
| Frison et al. | Enhanced retention of deammonification microorganisms for the treatment of psycrophilic anaerobic digestate | |
| Lee et al. | Advanced activated sludge processes toward circular bioeconomy | |
| Cai et al. | Factors of effecting hydrogen production from anaerobic fermentation of excess sewage sludge |